|
|
|
|
| LEADER |
01575nam a2200481Ia 4500 |
| 001 |
10-15585-MMWR-MM7103A2 |
| 008 |
220420s2022 CNT 000 0 und d |
| 020 |
|
|
|a 01492195 (ISSN)
|
| 245 |
1 |
0 |
|a Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022
|
| 260 |
|
0 |
|b Department of Health and Human Services
|c 2022
|
| 300 |
|
|
|a 5
|
| 856 |
|
|
|z View Fulltext in Publisher
|u https://doi.org/10.15585/MMWR.MM7103A2
|
| 650 |
0 |
4 |
|a adult
|
| 650 |
0 |
4 |
|a Adult
|
| 650 |
0 |
4 |
|a advisory committee
|
| 650 |
0 |
4 |
|a Advisory Committees
|
| 650 |
0 |
4 |
|a drug approval
|
| 650 |
0 |
4 |
|a Drug Approval
|
| 650 |
0 |
4 |
|a Food and Drug Administration
|
| 650 |
0 |
4 |
|a herpes zoster
|
| 650 |
0 |
4 |
|a Herpes Zoster
|
| 650 |
0 |
4 |
|a Herpes Zoster Vaccine
|
| 650 |
0 |
4 |
|a human
|
| 650 |
0 |
4 |
|a Humans
|
| 650 |
0 |
4 |
|a Immunocompromised Host
|
| 650 |
0 |
4 |
|a immunocompromised patient
|
| 650 |
0 |
4 |
|a middle aged
|
| 650 |
0 |
4 |
|a Middle Aged
|
| 650 |
0 |
4 |
|a recombinant vaccine
|
| 650 |
0 |
4 |
|a United States
|
| 650 |
0 |
4 |
|a United States
|
| 650 |
0 |
4 |
|a United States Food and Drug Administration
|
| 650 |
0 |
4 |
|a Vaccines, Synthetic
|
| 650 |
0 |
4 |
|a varicella zoster vaccine
|
| 700 |
1 |
0 |
|a Anderson, T.C.
|e author
|
| 700 |
1 |
0 |
|a Dooling, K.L.
|e author
|
| 700 |
1 |
0 |
|a Guo, A.
|e author
|
| 700 |
1 |
0 |
|a Kotton, C.N.
|e author
|
| 700 |
1 |
0 |
|a Lee, G.M.
|e author
|
| 700 |
1 |
0 |
|a Leidner, A.J.
|e author
|
| 700 |
1 |
0 |
|a Masters, N.B.
|e author
|
| 700 |
1 |
0 |
|a Shepersky, L.
|e author
|
| 773 |
|
|
|t Morbidity and Mortality Weekly Report
|
